Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results
暂无分享,去创建一个
Harvey J Clewell | Melvin E Andersen | Miyoung Yoon | Jerry L. Campbell | M. Andersen | H. Clewell | Jerry L Campbell | M. Yoon | J. Campbell
[1] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[2] N. Hariparsad,et al. In vitro methods in human drug biotransformation research: implications for cancer chemotherapy. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[3] J V Castell,et al. Human hepatocytes as a tool for studying toxicity and drug metabolism. , 2003, Current drug metabolism.
[4] Robert J Kavlock,et al. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[5] G. L. Kedderis,et al. Incorporating human interindividual biotransformation variance in health risk assessment. , 2002, The Science of the total environment.
[6] José Vicente Castell,et al. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. , 2007, Chemico-biological interactions.
[7] G. Loizou,et al. Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.
[8] G. L. Kedderis,et al. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. , 1996, Toxicology and applied pharmacology.
[9] Andreas P. Freidig,et al. Use of Physiologically Based Biokinetic (PBBK) Modeling to Study Estragole Bioactivation and Detoxification in Humans as Compared with Male Rats , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[10] J. DeJongh,et al. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans , 1997, Archives of Toxicology.
[11] Bas J Blaauboer,et al. The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[12] Hasso Seibert,et al. Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorophenols in vitro. , 2002, Toxicology.
[13] P. Olinga,et al. Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver. , 2008, Toxicology in Vitro.
[14] Rogelio Tornero-Velez,et al. Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. , 2010, Toxicology and applied pharmacology.
[15] M Liebsch,et al. The ECVAM Prevalidation Study on the Use of EpiDerm for Skin Corrosivity Testing , 2000, Alternatives to laboratory animals : ATLA.
[16] Tony Cox,et al. The Impact of Cytochrome P450 2E1‐Dependent Metabolic Variance on a Risk‐Relevant Pharmacokinetic Outcome in Humans , 2003, Risk analysis : an official publication of the Society for Risk Analysis.
[17] M. E. Hahn,et al. Serum alters the uptake and relative potencies of halogenated aromatic hydrocarbons in cell culture bioassays. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[18] Kazuya Maeda,et al. In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters , 2010, Drug Metabolism and Disposition.
[19] M. Finel,et al. Caco-2 cell monolayers as a tool to study simultaneous phase II metabolism and metabolite efflux of indomethacin, paracetamol and 1-naphthol. , 2010, International journal of pharmaceutics.
[20] John C Lipscomb,et al. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment , 2001, Toxicology and industrial health.
[21] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[22] J. Hochman,et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. , 2000, The Journal of pharmacology and experimental therapeutics.
[23] M. Jamei,et al. Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.
[24] Harvey J Clewell,et al. Development of a Screening Approach to Interpret Human Biomonitoring Data on Volatile Organic Compounds: Reverse Dosimetry on Biomonitoring Data for Trichloroethylene , 2007, Risk analysis : an official publication of the Society for Risk Analysis.
[25] J. Hochman,et al. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[26] Bas J Blaauboer,et al. Biokinetic Modeling and in Vitro–in Vivo Extrapolations , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[27] M. D. Barratt,et al. Prediction of toxicity from chemical structure , 2004, Cell Biology and Toxicology.
[28] I. A. D. de Graaf,et al. In vitro methods to study intestinal drug metabolism. , 2007, Current drug metabolism.
[29] Andrew Campbell. Development of PBPK model of molinate and molinate sulfoxide in rats and humans. , 2009, Regulatory toxicology and pharmacology : RTP.
[30] G. L. Kedderis. Extrapolation of in vitro enzyme induction data to humans in vivo. , 1997, Chemico-biological interactions.
[31] R. Voorman,et al. Comparison of Skin Esterase Activities from Different Species , 2006, Pharmaceutical Research.
[32] D Mackay,et al. Correlation of tissue, blood, and air partition coefficients of volatile organic chemicals. , 1989, British journal of industrial medicine.
[33] Hasso Seibert,et al. In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro. , 2003, Toxicology.
[34] I. Sipes,et al. Metabolism of bisphenol a in primary cultured hepatocytes from mice, rats, and humans. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[35] L. Gribaldo,et al. Report of the International Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity , 2000 .
[37] Anna Forsby,et al. Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity , 2007, Human & experimental toxicology.
[38] J W Fisher,et al. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.
[39] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[40] M L Gargas,et al. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. , 1993, Toxicology and applied pharmacology.
[41] O. Pelkonen,et al. In vitro–in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[42] Stefan S De Buck,et al. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation , 2007, Expert opinion on drug metabolism & toxicology.
[43] George Loizou,et al. MEGen: A Physiologically Based Pharmacokinetic Model Generator , 2011, Front. Pharmacol..
[44] H Seibert,et al. Influence of protein binding and lipophilicity on the distribution of chemical compounds in in vitro systems. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.
[45] J B Houston,et al. The Integrated Use of Alternative Methods in Toxicological Risk Evaluation , 1999, Alternatives to laboratory animals : ATLA.
[46] Hayley S. Brown,et al. Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.
[47] C Timchalk,et al. Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. , 2008, Neurotoxicology.
[48] W. T. Berge,et al. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. , 2011, The Annals of occupational hygiene.
[49] S. Schenker,et al. Drug disposition and liver disease. , 1975, Drug metabolism reviews.
[50] A. Guillouzo,et al. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[51] P. Potter,et al. Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. , 2007, Toxicology and applied pharmacology.
[52] M. Madden,et al. Extrahepatic Metabolism by CYP2E1 in PBPK Modeling of Lipophilic Volatile Organic Chemicals: Impacts on Metabolic Parameter Estimation and Prediction of Dose Metrics , 2007, Journal of toxicology and environmental health. Part A.
[53] Ugo Zanelli,et al. Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs , 2012, Drug Metabolism and Disposition.
[54] N. Kramer,et al. Measuring, modeling, and increasing the free Concentration of test Chemicals in cell assays , 2010 .
[55] B. Burchell,et al. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.
[56] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[57] G R Wilkinson,et al. Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.
[58] J. Gillette. FACTORS AFFECTING DRUG METABOLISM , 1971, Annals of the New York Academy of Sciences.
[59] P. Worboys,et al. Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery. , 2010, Combinatorial chemistry & high throughput screening.
[60] U. Fagerholm. Prediction of human pharmacokinetics—evaluation of methods for prediction of hepatic metabolic clearance , 2007, The Journal of pharmacy and pharmacology.
[61] Jun-yan Hong,et al. Acetone catabolism by cytochrome P450 2E1: studies with CYP2E1-null mice. , 1999, Biochemical pharmacology.
[62] J Brian Houston,et al. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. , 2006, Biochemical pharmacology.
[63] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[64] Robert J Riley,et al. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.
[65] I. Arisi,et al. Cell growing density affects the structural and functional properties of Caco‐2 differentiated monolayer , 2011, Journal of cellular physiology.
[66] H Seibert,et al. Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. , 2002, Toxicology in vitro : an international journal published in association with BIBRA.
[67] B J Blaauboer,et al. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. , 2003, Toxicology letters.
[68] J. Caldwell,et al. Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1'-hydroxyestragole. , 1987, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[69] Edward Ohanian,et al. Toxicokinetics and Risk Assessment , 2006 .
[70] J B Houston,et al. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.
[71] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[72] Bas J Blaauboer,et al. The Necessity of Biokinetic Information in the Interpretation of In Vitro Toxicity Data , 2002, Alternatives to laboratory animals : ATLA.
[73] Benoît Schilter,et al. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. , 2008, Toxicology and applied pharmacology.
[74] Malcolm Rowland,et al. Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[75] Yuichi Sugiyama,et al. Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.
[76] Benoît Schilter,et al. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[77] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[78] Rogelio Tornero-Velez,et al. Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[79] Robert J Kavlock,et al. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[80] P. Artursson,et al. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.
[81] Michael Balls,et al. Replacement Alternatives in Teaching. Progress in the reduction, refinement and replacement of Animal Experimentation , 1999 .
[82] Kati-Sisko Vellonen,et al. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[83] J. Galsworthy. A commentary , 1908 .
[84] D. Shen,et al. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. , 1997, Advanced drug delivery reviews.
[85] Hasso Seibert,et al. Validation of a prediction model for estimating serum concentrations of chemicals which are equivalent to toxic concentrations in vitro. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[86] Teruko Imai,et al. Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.
[87] Xing Han,et al. Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[88] Yuichi Sugiyama,et al. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. , 2009, Drug metabolism and pharmacokinetics.
[89] Johannes J M van de Sandt,et al. Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. , 2006, Toxicology letters.
[90] P. Beaune,et al. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. , 1997, Toxicology and applied pharmacology.
[91] C. Mendel,et al. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. , 1992, Journal of andrology.
[92] A. Stammati,et al. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics , 2005, Cell Biology and Toxicology.
[93] B J Blaauboer,et al. Toxicodynamic modelling and the interpretation of in vitro toxicity data. , 2001, Toxicology letters.
[94] J. Lipscomb,et al. Differences between Human and Rat Intestinal and Hepatic Bisphenol A Glucuronidation and the Influence of Alamethicin on In Vitro Kinetic Measurements , 2010, Drug Metabolism and Disposition.
[95] P. Olinga,et al. Precision-cut tissue slices as a tool to predict metabolism of novel drugs , 2007, Expert opinion on drug metabolism & toxicology.
[96] Andrew Worth,et al. Metabolism: A Bottleneck in In Vitro Toxicological Test Development , 2006, Alternatives to laboratory animals : ATLA.
[97] John C Lipscomb,et al. In vitro measurements of metabolism for application in pharmacokinetic modeling. , 2008, Pharmacology & therapeutics.
[98] M. Miller,et al. Comparison of human and rat metabolism of molinate in liver microsomes and slices. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[99] Timothy S Tracy,et al. Studying cytochrome P450 kinetics in drug metabolism. , 2008, Expert opinion on drug metabolism & toxicology.
[100] W. Kluwe,et al. Overview of phthalate ester pharmacokinetics in mammalian species. , 1982, Environmental health perspectives.
[101] Hugh A Barton,et al. Computational Modeling of Serum‐Binding Proteins and Clearance in Extrapolations Across Life Stages and Species for Endocrine Active Compounds , 2004, Risk analysis : an official publication of the Society for Risk Analysis.
[102] Aleksandra Galetin,et al. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.
[103] Justin Teeguarden,et al. Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[104] Yuan Chen,et al. Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450 , 2011, Drug Metabolism and Disposition.
[105] H Seibert,et al. Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.
[106] K. Knights,et al. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential , 2010, Drug metabolism reviews.
[107] Jörg C Gerlach,et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.
[108] M. Finel,et al. The Expression of Most UDP-Glucuronosyltransferases (UGTs) Is Increased Significantly during Caco-2 Cell Differentiation, whereas UGT1A6 Is Highly Expressed Also in Undifferentiated Cells , 2008, Drug Metabolism and Disposition.
[109] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[110] N. Vermeulen,et al. The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene. , 2002, Environmental toxicology and pharmacology.
[111] H. Cross,et al. An Inter-laboratory Study to Evaluate the Effects of Medium Composition on the Differentiation and Barrier Function of Caco-2 Cell Lines , 2005, Alternatives to laboratory animals : ATLA.
[112] P. van Bladeren,et al. A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. , 1997, Toxicology and applied pharmacology.
[113] Walter Schmitt,et al. General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.
[114] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.